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Cerebral palsy (CP) is the most common motor disability in childhood. This syndrome 
is the manifestation of intrauterine pathologies, intrapartum complications, and the 
postnatal sequel, especially among preterm neonates. A double hit model theory is 
proposed suggesting that an intrauterine condition along with intrapartum or postnatal 
insult lead to the development of CP. Recent reports demonstrated that treatment during 
the process of preterm birth such as magnesium sulfate and postnatal modalities such 
as cooling may prevent or reduce the prevalence of this syndrome. Moreover, animal 
models demonstrated that postnatal treatment with anti-inflammatory drugs coupled 
with nanoparticles may affect the course of the disease in pups with neuroinflammation. 
This review will describe the changes in the epidemiology of this disease, the underlying 
prenatal mechanisms, and possible treatments that may reduce the prevalence of CP 
and alter the course of the disease.
Keywords: cerebral palsy, neuroinflammation, progesterone, N-acetyl cysteine, nanoparticles, magnesium 
sulfate, birth asphyxia, intrauterine infection
iNTRODUCTiON
Cerebral palsy (CP) is the most common motor disability in childhood (1). CP is a heterogeneous 
group of clinical syndromes that describe permanent disorders of movement and posture. It  is 
characterized by abnormal muscle tone, posture, and movement, thereby limiting the activity of 
the affected person. The motor disorders of CP are often accompanied by disturbances of sensa-
tion, perception, cognition, communication and behavior, epilepsy, and secondary musculoskeletal 
problems (2). These disorders are attributed to non-progressive disturbances in the developing 
fetal brain (2), alteration in fetal development (2), pathologic intrauterine processes (3–8), or 
considered as prematurity complication (9). Although CP itself is not a progressive disease, its 
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clinical expression may change over time as the brain matures. 
In this review, we describe the changes in the epidemiology of 
this disease and the underlying prenatal mechanisms as well as 
possible treatments that may reduce its prevalence and alter the 
course of the disease.
ePiDeMiOLOGY OF CP
Population-based studies from around the world report that the 
prevalence estimates of CP range from 1.5 to more than 4 per 
1,000 live births or children of a defined age range (10–14). The 
overall birth prevalence of CP is approximately 2 per 1,000 live 
births (15–17).
A population-based study from the USA reported a relatively 
stable rate of spastic CP, 1.86/1,000 in 1985 to 1.76/1,000 in 
2002. Of interest, there were racial disparities in the changes 
of the prevalence of CP along that time period: while in non-
Hispanic White population, the overall prevalence declined 
from 1.65/1,000 in 1985 to 1.34/1,000 in 2002, the prevalence of 
CP in non-Hispanic Blacks increased from 2.29/1,000 in 1985 
to 2.34/1,000 in 2002 (18). The 2012–2013 National Survey of 
Children’s Health (NSCH) and the 2011–2013 National Health 
Interview Survey (NHIS) determined the prevalence of CP 
through parents’ reports among children aged 2–17 years. These 
surveys found a CP prevalence per 1,000 live births that ranged 
from 2.6 in the NSCH to 2.9 in the NHIS (19). In a population-
based study from Iceland (20), the prevalence of CP per 1,000 
live births did not change significantly from 1990 to 2003, which 
stayed between 2.2 and 2.3. However, it decreased from 1.5 to 
0.9/1,000 live births for children born at term, was stable for 
preterm births, and increased from 33.7 to 114.6/1,000 live births 
for very preterm births. An observation that may explain some 
of these findings is the parallel increase in the rate of cesarean 
sections. The Australian Cerebral Palsy Register, including infor-
mation from 1993 to 2006 reported an overall CP prevalence of 
2.1 per 1,000 live births with high prevalence in multiples (7 per 
1,000 live births) and in extremely low birthweight neonates 
(e.g., for birthweight <1,000 g, the prevalence was 50 per 1,000 
live births) (21). Overall, the total rate of CP is relatively stable, 
yet the contribution of prematurity and its complication to 
the prevalence of this syndrome are steadily increasing due to 
improvements in obstetric and neonatal care.
RiSK FACTORS FOR CP
Cerebral palsy can be derived from any event that will affect the 
fetal and neonatal developing brain. Indeed, congenital malfor-
mations, fetal growth restriction, multiple gestations, infection 
during the fetal and neonatal period, birth asphyxia, preterm 
delivery, untreated maternal hypothyroidism, perinatal stroke, 
and thrombophilia were all recognized as risk factors for CP 
(22–25). Premature birth, especially before 28 weeks of gesta-
tion, is the leading risk factor for the development of CP (26). 
The birth prevalence of CP is far higher in preterm than in term 
infants, increases with decreasing gestational age at delivery (27, 
28), and can reach up to 15% among preterm neonates who were 
born between 24 and 27  weeks of gestation (29). Indeed, the 
prevalence in 1,000 live births of CP among neonates who were 
born prior to 28  weeks of gestation is 82, and it decreases to 
1.4 at 36 weeks of gestation (30). Of interest, although preterm 
delivery is a well-established risk factor for CP, a recent study 
suggests that postterm pregnancy at 42  weeks or later is also 
associated with an increased risk of this condition (31).
Placenta-Mediated Pregnancy 
Complications
The impact of fetal growth restriction on the prevalence of 
CP is well established. The prevalence of this disease among 
neonates weighing <1,500  g is 59.2/1,000 live births, in 
comparison to 1.33/1,000 live births among those weighing 
>2,500  g (30). This association is independent of gestational 
age at delivery and extenuated by the presence of congenital 
anomalies, especially of the central nervous system (32). In an 
Australian population-based study (33) of singleton pregnan-
cies delivered ≥35 weeks of gestation, the authors identified 494 
children with CP. Growth restriction was prevalent in 16.5% 
of the neonates with CP, and the odds of these children to be 
growth restricted in comparison to those without was 3.5 (95% 
CI 2.2–5.5). A population-based study in Denmark reported a 
CP prevalence of 1.95/1,000 live births. CP was associated with 
an increased head/abdominal circumference ratio and cephalic 
index regardless of gestational age (34). Thus, the intrauterine 
processes associated with fetal growth restriction also lead to 
neuronal damage and subsequent CP.
The association between preeclampsia and subsequent devel-
opment of CP was under constant debate. However, a recent 
population-based cohort study demonstrated that early-onset 
preeclampsia is an independent risk factor for CP (OR 8.639, 95% 
CI 4.269–17.480) after adjustment for fetal growth restriction 
and gestational age at delivery. This was not the case regarding 
preeclampsia at term (6).
Congenital Malformations
The association between congenital malformations and subse-
quent CP is well documented. Major birth defects were the most 
frequently occurring risk factor in children with CP, and when 
combined with fetal growth restriction, they were associated with 
the highest relative risk (33). Congenital microcephaly is the most 
common birth defect in CP (35). Other non-cerebral malforma-
tions were also frequently coexisting with CP, especially cardiac 
(12%), urinary (5.4%), and musculoskeletal (5.4%) (36).
Multiple Gestations
Twins have a higher frequency of malformations and CP than 
singletons (37, 38). Indeed, among twin gestations, an affected 
twin with CP increases the risk by a factor of 15 that the other one 
will have this syndrome as well (35). Additionally, the in utero 
death of one twin, even if it occurs early in gestation, leaves 
the surviving twin at markedly increased risk for CP (39). The 
prevalence of CP in an Australian study (40) was 1.6, 7.3, and 
28 per 1,000 births in singletons, twins, and triplets, respectively. 
The authors also reported that in the case of co-twin death, the 
risk for CP increases by a factor of 8, from 12/1,000 to 96/1,000. 
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The explanation for this observation was that the dissolving twin 
releases thromboplastin and emboli that may lead to brain injury 
of the surviving twin and subsequent development of CP.
Perinatal Stroke
Fetal and neonatal cerebral accidents are associated with increased 
risk for subsequent development of CP. Indeed, among 100 full-
term neonates with the diagnosis of neonatal arterial ischemic 
stroke, born in Switzerland between 2000 and 2010, 39% were 
diagnosed as having CP at the age of two (41). In a report from 
California, USA, of 36 children with arterial ischemic stroke, 58% 
had subsequent CP. The mechanisms leading to perinatal strokes 
are not clear; in some cases, preeclampsia was proposed as a risk 
factor; in addition, there are those who relate that to placental 
vascular disorder. The association between CP and thrombophilia 
is not that clear. In an Australian population-based case–control 
study (42), among term neonates, there was no association 
between a single thrombophilic mutation and CP. Among pre-
term neonates with the MTHFR C677T mutation, those who were 
homozygous and were born between 32 and 36 weeks of gestation 
had an odd ratio (OR) of 2.55 (95% CI 1.12–5.74), while the het-
erozygous ones had an OR of 1.91 (95% CI 1.01–3.66) to develop 
any type of CP (42). This MTHFR mutation at the homozygous 
state, among preterm neonates born <32 weeks of gestation, was 
also associated with increased risk for diplegia (OR 2.76, 95% CI 
1.21–6.12), while the heterozygous was associated with a mildly 
increased risk for diplegia throughout gestation (OR 1.58, 95%, 
CI 1.02–2.45). A different mutation, MTHFR A1298C at the 
heterozygote state, was associated with risk reduction for diplegia 
in neonates born at 32–36 weeks of gestation (OR 0.16, 95% CI 
0.02–0.70). Among early preterm neonates (<32 weeks of gesta-
tion), FVL homozygosity may be associated with an increase in 
the risk of developing quadriplegia (OR 9.12, 95% CI 0.86–53.71). 
Heterozygous PGM and homozygous MTHFR C677T combined 
were associated with quadriplegia at all gestational ages (OR 
5.33, 95% CI 1.06–23.25) (42). On the other hand, an Israeli 
retrospective case–control study found no increased prevalence 
of thrombophilic mutations among children with non-stroke CP 
(43). The association between perinatal stroke and subsequent 
CP may suggest that these conditions may represent that in some 
of the cases, the course of progression of a disease, starting in the 
uterus, has a neonatal presentation as acute ischemic stroke and 
subsequently develop into CP. This hypothesis requires further 
investigation.
GeNeTiCS CONTRiBUTiONS TO CP
There are indications of genetic involvement in CP, and its 
contribution is estimated to be as high as 48% of term and 24% 
of preterm idiopathic cases (44). Genetic investigations of CP 
are performed using population-genetic and pedigree inquiries. 
Population-based genetic studies have identified several candi-
date genes, whose variants were more frequent in CP patients in 
certain populations, some of which are associated with processes 
of inflammation, coagulation, and blood flow (45–47). Pedigree 
studies are mostly aimed at specific forms of CP that are found to 
be frequent in some families. Specific CP forms, such as ataxic CP, 
symmetrical spastic CP, and tetraplegic CP with MR, comprise 
the minority of CP cases but exhibit strong inheritance patterns, 
most often autosomal recessive (48–50). One interesting case, 
involving a family with repeated congenital CP, has led to the 
identification of a candidate gene with an imprinting-like inherit-
ance pattern, whereas the mutation is expressed only when it is 
inherited from the father (51). This gene is crucial for normal 
fetal neurodevelopment, but its levels may also be decreased in 
the setting of hypoxia and low birth weight. It is suggested that 
this mechanism, as deduced from a pedigree data, may also play 
a role in sporadic CP cases (51).
MeCHANiSMS LeADiNG TO CP
Understanding the mechanisms leading to a disease is a crucial 
part in the development of treatment and prevention modali-
ties. We can divide the events leading to the development of CP 
into several categories: (1) predisposing intrauterine factors—
including fetal growth restriction, placental vascular disorders, 
intrauterine infection/inflammation, and congenital anomalies; 
(2) acute events at the peripartum period—placental abruption, 
chorioamnionitis, and birth asphyxia; and (3) events at the 
neonatal period—intraventricular hemorrhage, periventricular 
leukomalacia (PVL), sepsis, and neonatal stroke (Figure 1). In 
the next sections, we will discuss the effect of predisposing intrau-
terine factors, especially the role of infection and inflammation.
Placental Lesions and Their Association 
with CP
The placental histologic lesions enable us to identify some of the 
intrauterine pathological processes that may lead or contribute 
to the development of CP. The systematic approach of defining 
placental histologic lesions according to three major groups: 
(1) evidence of infection/inflammation; (2) maternal under perfu-
sion; and (3) fetal vascular thrombo-occlusive disease, contributed 
to further defining the association between specific placental 
lesions and subsequent abnormal neurocognitive development of 
the neonate. Indeed, lesions consistent with maternal under perfu-
sion including syncytial knots and atherosis were associated with an 
abnormal neonatal amplitude-integrated electroencephalographic 
(aEEG) recording during the first days of life of very preterm 
neonates (<28  weeks) (52) and a significant risk for subsequent 
development of CP (53). Moreover, the fetal inflammatory response 
in the placenta and villous edema are associated with subsequent 
abnormal cognitive testing in the child (53), and umbilical cord 
inflammation (funisitis) is associated with an increased risk for CP 
(54). Collectively, placental inflammatory and vascular lesions are 
associated with subsequent development of CP.
iNTRA-AMNiOTiC iNFeCTiON AND 
iNFLAMMATiON, FeTAL iNFLAMMATORY 
ReSPONSe SYNDROMe (FiRS), AND 
SUBSeQUeNT CP
Although fetal growth restriction (FGR) is a greater risk fac-
tor for CP than both birth asphyxia and fetal inflammation 
FiGURe 1 | Underlying mechanisms leading to cerebral palsy (CP). The mechanisms leading to cerebral palsy can be attributed to the following exposures: (1) 
intrauterine exposure including infection elicit a fetal inflammatory response syndrome and white matter damage in the fetus, fetal growth restriction, placental 
vascular disorders that are associated with vascular injuries in the fetal brain and congenital anomalies. (2) Intrapartum events that affect the fetus during the process 
of labor and delivery such as chorioamnionitis, birth asphyxia, and placental abruption are all acute events that are associated with further implication on the fetal/
neonatal brain. (3) Post-partum exposure to infection of prematurity complications that affect the neonate and subsequently lead to CP. These events can be 
isolated but also combined, and the two-hit theory proposed that a neonate who suffered from hostile intrauterine environment such as infection may be further 
affected by acute intrapartum event such as abruption or post-partum complication and develop CP.
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combined (33), intra-amniotic infection and inflammation 
are the only mechanisms in which there is an evidence of 
causality between the intrauterine process and PVL. Indeed, 
intrauterine administration of lipopolysaccharides (LPSs) to 
pregnant rabbits was associated with a significant increase in 
the rate of PVL in the pups of the treated vs. those of the 
untreated rabbits (55). Evidence from amniotic fluid cultiva-
tion suggests that in general, the intrauterine cavity is a sterile 
environment during the mid-trimester and the prevalence of 
infection and or inflammation (IAI) in mid-trimester amnio-
centesis is 0.4% (56). This value changes substantially in the 
presence of pathological processes; indeed, the rate of IAI in 
patients with prelabor rupture of membranes is about 30% (57), 
in those with preterm labor is 12% with intact membranes 
(57), and during term labor 18% (58). The rate of intrauterine 
inflammation is higher than that of intrauterine infection at 
any given gestational age. Indeed, between 20 and 24 weeks of 
gestation, the frequency of intrauterine inflammation is 70%, 
and that of positive amniotic fluid culture is 35%; these rates 
decrease between 20 and 27 weeks of gestation to 30 and 20%, 
respectively (59). Of note, there is a ninefold increase in CP 
for infants of mothers who had a fever during labor (24).
The FIRS is the most serious stage of IAI. It means that the 
ascending intrauterine infection or the inflammatory processes 
(like in FIRS type 2) affect the fetus. This syndrome is character-
ized by systemic activation of the fetal innate immune system 
similar to the adult systemic inflammatory response syndrome. 
FIRS was originally defined in fetuses with preterm labor and 
preterm PROM by an elevation of the fetal plasma interleukin-6 
concentration (7). Affected fetuses had evidence of multi-organ 
involvement, had a higher morbidity rate after adjustment for 
gestational age, and were more likely to have a subsequent 
spontaneous preterm delivery in cases of preterm PROM (7). 
FIRS can lead to multi-organ involvement in the following 
body systems; it can cause hematopoietic abnormalities (60, 
61), endocrine abnormalities as a result of “stress” (62, 63), 
cardiac dysfunction, especially diastolic (64), and brain injury 
in numerous mechanisms such as high tumor necrosis factor 
alpha (TNFα) concentrations in PVL infants (65). Indeed, in 
neonates with PVL, there is an increased immunoreactivity 
for TNFα in the neocortex, hippocampus, basal ganglia, and 
thalamus (66, 67). A live demonstration of the effect of fetal 
neuroinflammation on neonatal neurologic functions was 
recently reported. In a study on New Zealand white rabbits that 
had an intrauterine injection of E. coli LPS (55), their newborn 
pups suffered from neurobehavioral deficits and white matter 
injury (WMI). Moreover, in comparison with a group that 
had an intrauterine injection of sterile saline, the LPS-injected 
newborn pups had a greater mortality rate, were hypertonic, 
and demonstrated significant impairment in posture, righting 
reflex, locomotion, and feeding. The in utero LPS-exposed pups 
also had neuroinflammation indicated by activated microglia 
and hypomyelination in the periventricular regions. This phe-
notype resembles the one found in PVL and CP (55). Therefore, 
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collectively, the data presented here suggest that IAI has a causal 
role in the pathway that subsequently leads to the development 
of CP. This process requires fetal involvement in the form of 
FIRS, which in turn leads to brain dysfunction and premature 
labor which are suggested to cause CP (65). Finally, there are 
reports suggesting that CP may be the result of a two-hit model 
in which the mechanisms leading to the delivery of an affected 
neonate (i.e., preterm birth, fetal growth restriction, and birth 
asphyxia) are the first hit; while neonatal complications such 
as sequel of prematurity, sepsis, and others are the second hit 
that leads to abnormal neurodevelopment and subsequent CP 
(68). Evidence in support of this view are the finding by Mor 
et al. (6) regarding the mechanisms leading to CP in neonates 
with preeclampsia and the findings of Korzeniewski et al. (69) 
that “Chronic placental inflammation, acute fetal inflammation, 
and neonatal inflammation-initiating illness seem to interact 
in contributing risk information and/or directly damaging the 
developing brain of newborns delivered very preterm.”
Some examples of this hypothesis are that SGA newborns 
who also had systemic inflammation were at a greater risk of a 
low Bayley Mental Development score than their peers who had 
neither SGA nor systemic inflammation (68). This shows that a 
first hit (SGA) contributed less to developmental delay then SGA 
combined with a second hit such as systemic inflammation (68). 
Another example is that SGA combined with early preeclampsia 
was more prone to cause CP then SGA alone (6).
eNCePHALOPATHY OF PReMATURiTY 
(eOP)
Encephalopathy of prematurity is the leading risk factor for 
developing CP, indeed 20–60% of individuals who have EOP 
eventually develop CP (70). EOP is a complex amalgam of both 
destructive and developmental disturbances involving both 
gray matter and WMI in various brain areas resulting mainly 
from intrauterine hypoxia–ischemia and/or systemic infection/
inflammation (71). White and gray matter lesions are the most 
prevalent type of injury observable in the magnetic resonance 
images (MRIs) of children with CP, and a quantitative measure 
of gray and white matter lesion burden correlates with motor and 
cognitive dysfunction in children with unilateral CP (72).
White matter injury is well known as PVL and is a robust 
prognostic factor for CP (73). PVL is associated with reactive 
gliosis, excitotoxicity microglial activation, the release of free 
radicals, and subsequent hypomyelination. This type of injury 
is divided into cystic and diffuse. Cystic WMI are necrotic 
lesions with a loss of cellular elements partially filled by glial 
scars that can be detected by ultrasound. Its prevalence is 
declining, and it is now observed in only 5% of very-low-
birthweight survivors. Diffuse WMI is now the most common 
type of lesion (observed in 90% of infants with PVL and in 
50% of very-low-birthweight survivors) and is visualized via 
MRI. Rodent prenatal ischemia models have all reported dif-
fuse WMI in various brain areas as a finding consistent with 
EOP and CP (74).
Gray matter injury is related to neuronal and axonal degen-
eration including the somatosensory pathways. Several studies 
suggest that abnormal somatosensory inputs may be a causal 
factor of motor impairments in CP (71).
CAN we PReveNT OR ReDUCe THe 
RATe OF CP?
Any intervention that will lead to modification of the risk factors 
for CP as well as for the prevention or treatment of the underlying 
mechanisms that leads to this syndrome eventually will affect its 
prevalence. Therefore, we have three main approaches that will 
enable to reduce the rate of CP: (1) prevention of risk factors such 
as preterm birth; (2) affecting the disease process itself such as 
treatment with magnesium sulfate of patients who are about to 
deliver at early preterm; and (3) postexposure treatment of the 
affected neonate such as cooling of neonates with birth asphyxia 
(Figure  2). In the following paragraphs, we will discuss these 
strategies in relation to the most prominent risk factor for CP 
today, and that is preterm birth.
Prevention of Risk Factors
The basis of an effective preventive strategy of any disease is 
represented by setting the goals which we would like to achieve. 
In Obstetrics, this is either to avoid the development of the 
disease or to alleviate its clinical presentation in a way that will 
minimize maternal and fetal/neonatal morbidity and mortality. 
A basic tool for a successful preventive program is the ability 
to identify patients at risk and to tailor the treatment accord-
ing to the mechanisms of disease. A good example for this is 
the progress made during the last decade in the prevention 
of spontaneous premature birth. This progress is relevant to 
the potential reduction of CP since about half of the cases 
of this disease are due to prematurity and its complications. 
Indeed, the evidence that 17α-hydroxyprogesterone caproate 
can prevent recurrent preterm birth was presented at the end 
of the twentieth century (75, 76). Meis et al. (77) demonstrated 
that it can also improve neonatal outcome and turn it into 
the drug of choice for the secondary prevention of recurrent 
preterm birth. The second step in that direction was the fact 
that women who have a short cervix with or without a history 
of premature birth can benefit from vaginal progesterone for 
the prevention of premature birth and improvement of neonatal 
outcome (78–80). This finding led to the development of pri-
mary prevention of preterm birth in women with a short cervix. 
Overall, the administration of progesterone for the prevention 
of preterm birth reduced its rate in about 50% (79, 81). A cervi-
cal cerclage is an additional tool for the prevention of recurrent 
preterm birth in women with a short cervix. The Maternal-Fetal 
Medicine Units Network of the National Institutes of Health 
of the USA demonstrated in a multicenter randomized trial 
that in women with prior spontaneous preterm birth with a 
short cervix (<25 mm), cerclage reduced pre-viable birth and 
perinatal mortality but did not prevent deliveries <35  weeks, 
unless cervical length was shorter than 15 mm, in which recur-
rent preterm birth was reduced by 40–50% (82). Comparisons 
of the use of vaginal progesterone or cerclage were found to 
be equally efficacious in the prevention of preterm birth in 
women with a sonographic short cervix in the mid-trimester, 
FiGURe 2 | Strategies for the reduction of cerebral palsy (CP). The strategies to reduce the rate of CP are as follows: (1) prevention of adverse events during 
pregnancy mainly of preterm birth (spontaneous or indicated); (2) the administrations of supportive medical treatment during an acute event such as magnesium 
sulfate of betamethasone during preterm labor; and (3) postexposure treatment to reduce the neurologic injury.
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singleton gestation, and previous preterm birth. Selection of 
the optimal treatment needs to consider adverse events, cost, 
and patient/clinician preferences (83). The use of cervical pes-
sary for the prevention of preterm birth was also described. 
A randomized controlled trial, which studied pregnant women 
(aged 18–43 years) with a cervical length of 25 mm or less and 
divided them into two groups (one using cerclage and one that 
did not), found that spontaneous delivery before 34  weeks of 
gestation was significantly less frequent in the pessary group 
than in the expectant management group [12 (6%) vs. 51 
(27%), OR 0.18, 95% CI 0.08–0.37; p <  0.0001]. No serious 
adverse effects associated with the use of a cervical pessary 
were reported. Therefore, cervical pessary use could prevent 
preterm birth in a high-risk population with a short cervical 
length (84). Once again, when compared, cerclage, vaginal 
progesterone, and pessary appear to have similar effectiveness 
as management strategies in women with singleton pregnancy, 
previous spontaneous preterm birth, and a short cervix (85).
Aside from the prevention of spontaneous preterm parturition 
the reduction of placental-mediated pregnancy complications 
that necessitate indicated preterm birth can also attribute for the 
reduction in CP prevalence. Indeed, our group demonstrated 
an association between early-onset preeclampsia as well as 
IUGR and subsequent development of CP (6). Therefore, any 
intervention that will reduce the rate of early-onset disease or the 
development of IUGR will have a chance to reduce the risk of CP. 
Preliminary evidence suggests that aspirin (86), as well as low 
molecular heparins (87, 88), may be effective in the secondary 
prevention of placental-mediated diseases.
Collectively, all these treatments may affect the overall inci-
dence of CP by reducing the rate of preterm deliveries. However, 
as of today, there are neither reports in the literature to support 
this assumption nor any studies that were conducted to address 
this question. Moreover, although the rate of preterm delivery 
declined in the past few years, the major fraction in which the 
change occurred was that of the late preterm birth, although the 
CP is more prevalent among the early preterm birth and a change 
in this group may be observed only in a few more years.
Affecting the Disease Process
Recent years yielded evidence that the treatment of women with 
early preterm parturition with magnesium sulfate (MgSO4) can 
have a protective effect against the subsequent development 
of CP (89, 90), especially the severe phenotype (90). The large 
randomized controlled trial conducted by the Maternal-Fetal 
Medicine Units Network of the NICHD included 2,241 women 
with threatened preterm birth who were randomized to magne-
sium vs. placebo. In the primary composite outcome of neonatal 
death and CP, there was no statistical difference between the 
study groups. However, a secondary analysis revealed that 
the rate of moderate and severe CP was reduced substantially 
(relative risk, 0.55; 95% CI 0.32–0.95) (90). This observation was 
further supported by several meta-analyses (91–93). One of the 
meta-analyses reported that MgSO4 given to women at risk of 
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premature birth reduced the risk of CP by 30% (91). In addition, 
the authors reported that the number of mothers needed to treat 
to prevent one case of CP was 52 and that the cost to prevent one 
case of CP was 10,291$ (91). Therefore, MgSO4 should be consid-
ered for use in patients at high risk of delivery before 32 weeks of 
gestation (94). With this evidence at hand, a secondary analysis of 
the study by Kamyar et al. reported that in neonates with clinical 
chorioamnionitis, the beneficial effect of MgSO4 could not be 
demonstrated (95). Thus, in the general parturient of population 
who are at risk for preterm birth, the current approach is the 
antenatal administration of MgSO4 is associated with a reduction 
in the rate of severe to moderate CP.
A recent meta-analysis suggests that the prenatal admin-
istration of antenatal corticosteroids for fetal lung maturity is 
associated with a reduction in the rate of CP. This meta-analysis 
included 14 studies, and the antenatal administration of corticos-
teroids was associated with a significant reduction in the risk of 
CP, especially in neonates born prior to 28 weeks of gestation (96). 
Therefore, the current evidence suggests that antenatal treatment 
with corticosteroids and MgSO4 is associated with a significant 
reduction in the subsequent development of CP in preterm 
neonates, especially those who were born prior to 32 weeks of 
gestation. Further study is needed for the better identification 
of the specific patient population who will benefit from such an 
intervention in particular.
Postexposure Treatment of the Affected 
Neonate
The third option for intervention to prevent CP is the treat-
ment of the affected neonate postexposure. This treatment is 
more etiology driven than the previous modalities. Indeed, the 
administration of progesterone for the prevention of recurrent 
preterm birth is done across the board to all patients with 
a history of prior spontaneous preterm birth, and all women 
with threatened preterm delivery receive MgSO4, regardless of 
the etiology of the preterm parturition. This is not the case of 
postexposure interventions, for example, cooling has become 
a standard of care, and the hallmark of treatment of neonate 
who had birth asphyxia (97, 98). Yet, this topic is extensively 
reviewed elsewhere (99).
Since EOP is both destructive and developmental in origin, 
therapeutic interventions—both early neuroprotective (that 
were discussed above) and later restorative—must address 
this complexity. Restorative therapies are evolving recently in 
animal models and include, for example, (1) glial-restricted 
precursor (GRP) cell transplantation in an ischemic neonatal 
WMI mouse model. Transplantation did not enhance survival, 
but behavioral and neuropathological outcomes were improved 
after GRP transplantation (100). (2) Nanomedicine is a new 
frontier in the development of therapies for the treatment of 
brain injury resulting in CP. Nanomaterials such as dendrimers 
provide opportunities for the targeted delivery of multiple drugs 
that can mitigate several pathways involved in injury and can be 
delivered specifically to the cells that are responsible for injury 
(101). (3) Allogeneic umbilical cord blood (UCB) has therapeu-
tic potential for CP. An experimental study in an animal model 
of CP showed therapeutic effects of intraperitoneally adminis-
tered UCB cells, with the incorporation of these cells into the 
brain lesion (102). Concomitant administration of recombinant 
human erythropoietin may boost the efficacy of UCB, as it has 
neurotrophic effects (103). The window for restorative therapy 
depends on the therapy itself as described above, and to this 
date, there are no restorative therapies that were proven to help 
CP patients.
This area is still experimental in most and based on animal 
models and will not be furthermore discussed in this article.
Another emerging topic in the area of postexposure therapy is 
stem cell therapy. Recent studies researched the use of embryonic 
stem cells (EST) in the treatment of CP. EST were found to improve 
the sight of children with CP and cortical visual impairment. Out 
of 40 children in the study, 39 have shown improvement in sight 
after this treatment (104). UCB was found to have a small statis-
tically significant intervention on gross motor skills of children 
corn with CP (105).
CONCLUSiON
Cerebral palsy is a neurologic motor disorder that can be the result 
of several underlying mechanisms during intrauterine life or at 
the newborn period. The risk for CP is gestational age depend-
ent, and it is much more prevalent among preterm neonates, 
especially those who were extremely premature. Treatments and 
intervention that prevent preterm birth or assist the premature 
fetus during parturition, and postnatal intervention, may reduce 
the incidence of this syndrome in the near future. Moreover, 
emerging evidence suggests that the understanding of the 
mechanisms leading to CP will facilitate targeted treatment for 
the affected child.
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